Betamethasone Phosphoric Acid

Summary

Betamethasone Phosphoric Acid (CHEMBL1201207) is an approved small-molecule anti-inflammatory agent; indicated across 2 conditions including plantar fasciitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Chemistry: 472.4 Da · C22H30FO8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201207
Name	Betamethasone Phosphoric Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	107782
ChEBI	CHEBI:68603
Molecular formula	C22H30FO8P
Molecular weight	472.4
InChIKey	VQODGRNSFPNSQE-DVTGEIKXSA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C

IUPAC name: [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate

ChEBI definition: A steroid phosphate that is the 21-O-phospho derivative of betamethasone.

Pharmacological roles (ChEBI): anti-inflammatory agent, immunosuppressive agent.

Also known as: Betamethasone phosphoric acid, Betamethasone phosphate, betamethasone phosphate, Betamethasone Phosphate, BETAMETHASONE PHOSPHORIC ACID

Parent form; salt/anhydrous children: CHEMBL1200762

Patent coverage: 333 distinct patent families (954 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Muscarinic acetylcholine receptor M4, Glucocorticoid receptor, Muscarinic acetylcholine receptor M5, Muscarinic acetylcholine receptor M1, Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, Histamine H1 receptor, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	8.43	Ki	3.73	nM	CHEMBL_ACT_7620984
NR3C1	8.09	IC50	8.22	nM	CHEMBL_ACT_7620983
HRH1	5.93	Ki	1169	nM	CHEMBL_ACT_7620996
CHRM3	5.87	Ki	1363	nM	CHEMBL_ACT_7621028
CHRM1	5.78	Ki	1676	nM	CHEMBL_ACT_7621024
CHRM4	5.78	Ki	1663	nM	CHEMBL_ACT_7621030
PIN1	5.66	Kd	2200	nM	CHEMBL_ACT_25072977
CHRM5	5.25	Ki	5648	nM	CHEMBL_ACT_7621032
CHRM3	5.19	IC50	6429	nM	CHEMBL_ACT_7621027
CHRM1	5.16	IC50	6959	nM	CHEMBL_ACT_7621023
CHRM5	5.11	IC50	7861	nM	CHEMBL_ACT_7621031
HRH1	5	IC50	10060	nM	CHEMBL_ACT_7620995

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plantar fasciitis	1	MONDO:0004833	EFO:1001909

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).